#United States #New York #Class Action #The Gross Law Firm #Unicycive Therapeutics

Class Action Notice for Unicycive Therapeutics Shareholders

Shareholders who experienced financial losses in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) have been alerted to the opportunity to engage in a class action lawsuit led by The Gross Law Firm. This action targets shareholders who acquired shares during the specified class period, which covers from March 29, 2024, to June 27, 2025. The deadline for prospective plaintiffs to register their intent to participate in the lawsuit as lead plaintiffs is set for October 14, 2025.

What Allegations Arise?

According to the allegations put forth in the complaint, Unicycive Therapeutics and its associated parties are claimed to have made materially false and misleading statements regarding the company's readiness to comply with the FDA’s manufacturing standards. Furthermore, the allegations highlight that the prospects for the regulatory approval of the oxylanthanum carbonate new drug application were exaggerated. As a result, the company’s public communications were misleading and misrepresented the true nature of Unicycive’s operational stability and regulatory compliance

Importance of Participation

Shareholders who have invested in Unicycive during the class period are highly encouraged to join this action as it seeks to recover losses incurred due to the alleged misconduct by the company. Registering for participation in this class action provides individuals with the chance to stay informed about the developments of the case through portfolio monitoring software. This service will ensure shareholders receive timely updates and are aware of their rights and the ongoing proceedings.

Joining the Class Action

Interested shareholders can easily register their participation through the Gross Law Firm's online platform. The registration process requires sharing basic information for enrollment; however, it is essential to note that opting to act as a lead plaintiff is entirely optional, and there is no financial obligation or fees involved in participating. This class action represents an opportunity for individuals to seek justice and compensation for their losses without facing any upfront costs.

Why Choose The Gross Law Firm?

The Gross Law Firm has established itself as a prominent advocate for shareholders across the nation. The firm is dedicated to holding corporations accountable for fraudulent activities while defending investors' rights in various class action lawsuits. The commitment of The Gross Law Firm extends beyond mere legal representation; they ensure companies adhere to ethical business practices, which is vital for fostering a trustworthy investment landscape.

Shareholders who suspect that they've suffered losses should seriously consider joining the class action against Unicycive Therapeutics. By asserting their rights through representation, they can contribute to holding the company responsible for any alleged deceit and misleading information provided by its executives. For further details, please visit The Gross Law Firm’s website or contact their office directly for personalized assistance.

Key Takeaways

• - Class period: March 29, 2024 – June 27, 2025
• - Deadline for lead plaintiff registration: October 14, 2025
• - Contact information for The Gross Law Firm: 15 West 38th Street, 12th floor, New York, NY, 10018 | Phone: (646) 453-8903 | Email: [email protected]
• - Free and no-cost participation: Engaging in this class action does not require any financial commitment, ensuring no risk for shareholders to take action against perceived fraud.

In conclusion, shareholders of Unicycive Therapeutics, Inc. have a crucial opportunity to stand together against corporate malfeasance. Joining the class action is a decisive step towards protecting individual investments and holding the company accountable for its alleged misrepresentations.